<DOC>
	<DOCNO>NCT00832182</DOCNO>
	<brief_summary>This trial conduct Europe Asia . The aim clinical trial investigate long-term safety insulin aspart management type 1 diabetes . An extension ANA/DCD/065 trial</brief_summary>
	<brief_title>Examining Long-term Safety Insulin Aspart When Used Part Treatment Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>Signed informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) The subject must complete ANA/DCD/065 trial Impaired hepatic function Impaired renal function Total daily insulin requirement 1.4 U/kg Cardiac problem Uncontrolled hypertension Known suspect allergy trial product relate product Current hypoglycaemic unawareness judge investigator Known suspect abuse alcohol narcotic Women breastfeed intention become pregnant , judge use adequate contraceptive measure ( adequate measure intrauterine device ( IUD ) , oral contraception barrier method ) Any condition Investigator and/or Sponsor feel would interfere trial participation evaluation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>